Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013) (NCT04624204)
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Pembrolizumab (MK-3475) in Combination With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib (MK-7339), Compared to Concurrent Chemoradiation Therapy Alone in Participants With Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC)
🩺 Plain-English Summary (8th-Grade Level)
Researchers are looking for new ways to treat Limited-Stage Small Cell Lung Cancer (LS-SCLC), a type of lung cancer that has not spread from the lung to other parts of the body. The purpose of this study is to learn if pembrolizumab and olaparib, when given with chemotherapy and radiation treatment (CRT), can be effective in treating LS-SCLC. The researchers want to know if participants who receive CRT and pembrolizumab, with or without olaparib, have a longer overall survival compared to participants who only receive CRT.
Who can join: Review the eligibility criteria below.
Location: Ironwood Cancer & Research Centers ( Site 0007) — Chandler, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (187 Sites)
Showing the first 25 of 187 sites.
- Ironwood Cancer & Research Centers ( Site 0007) — Chandler, Arizona
- Loma Linda University Cancer Center ( Site 0011) — Loma Linda, California
- Georgetown University ( Site 0017) — Washington D.C., District of Columbia
- Moffitt Cancer Center ( Site 0137) — Tampa, Florida
- University of Chicago Medical Center ( Site 0136) — Chicago, Illinois
- Fort Wayne Medical Oncology and Hematology ( Site 0034) — Fort Wayne, Indiana
- University of Kentucky Chandler Medical Center ( Site 0138) — Lexington, Kentucky
- Overton Brooks VAMC ( Site 0041) — Shreveport, Louisiana
- Harry & Jeanette Weinberg Cancer Institute ( Site 0045) — Baltimore, Maryland
- VA Ann Arbor Healthcare System ( Site 0050) — Ann Arbor, Michigan
- St. Vincent Healthcare Frontier Cancer Center ( Site 0056) — Billings, Montana
- Oncology Hematology West, PC dba Nebraska Cancer Specialists ( Site 0061) — Omaha, Nebraska
- Memorial Sloan Kettering - Basking Ridge ( Site 0133) — Basking Ridge, New Jersey
- John Theurer Cancer Center ( Site 0064) — Hackensack, New Jersey
- Memorial Sloan Kettering - Monmouth ( Site 0135) — Middletown, New Jersey
- Memorial Sloan Kettering - Bergen ( Site 0130) — Montvale, New Jersey
- Rutgers Cancer Institute of New Jersey ( Site 0123) — New Brunswick, New Jersey
- Memorial Sloan Kettering- Commack ( Site 0132) — Commack, New York
- Memorial Sloan Kettering - Westchester-Thoracic Oncology ( Site 0134) — Harrison, New York
- Memorial Sloan Kettering Cancer Center ( Site 0069) — New York, New York
- Memorial Sloan Kettering - Nassau ( Site 0131) — Uniondale, New York
- Fairview Hospital-Moll Cancer Center ( Site 0141) — Cleveland, Ohio
- Cleveland Clinic Main ( Site 0139) — Cleveland, Ohio
- Cleveland Clinic - Hillcrest Hospital-Hillcrest Hospital Cancer Center ( Site 0140) — Mayfield Heights, Ohio
- Penn State Hershey Cancer Institute ( Site 0081) — Hershey, Pennsylvania
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Small Cell Lung Cancer
- Ipilimumab and Nivolumab in Recurrent Extensive Stage Small Cell Lung Cancer After Receiving Platinum-based Chemotherapy — New Haven, Connecticut
- Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC) — Irvine, California
- Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy — Tucson, Arizona
- Pharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms — Rockville, Maryland
- PF-07104091 as a Single Agent and in Combination Therapy — Clive, Iowa
Explore by condition: All Small Cell Lung Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.